Alzheimer's Disease Research Center
Search All News
The goal of the ADRC HS Scholars Program is to reach talented young people from backgrounds underrepresented in science and medicine, and to encourage and inspire them toward careers in these fields.
Adam M. Brickman, PhD, Professor of Neuropsychology, and Scott A. Small, MD, Boris and Rose Katz Professor of Neurology, discuss their study that examined health benefits of flavanol-rich diet
Scott Small, MD, Boris & Rose Katz Professor of Neurology and Director & Alzheimer's Disease Research Center at CUIMC talks about the study that examined flavanols levels and memory loss
- August 31, 2022
Dr. James M. Noble is an associate professor of neurology and dementia specialist in the Division of Aging and Dementia.
- December 28, 2021
Columbia research seven years in the making highlights potential therapeutic target for neurodegenerative disease
- June 28, 2021
The federal health insurance program may limit who can get the drug, which Biogen priced at $56,000 a year, to limit the financial impact
- June 8, 2021
On Monday, the FDA approved a new drug for Alzheimer’s disease—the first in nearly two decades. Biogen’s aducanumab aims to slow the cognitive decline often associated with the disease.
- June 4, 2021
Other researchers are not convinced that these biomarkers vary by race, primarily because so little Alzheimer’s research has been conducted on Black and Latinx people.